Ocular Therapeutix (OCUL) Announces OTX-DP Met Primary Endpoints in First Phase 3
Tweet Send to a Friend
Ocular Therapeutix (NASDAQ: OCUL) announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
